论文部分内容阅读
本刊讯(通讯员胡振栋张建平)近日,湖北长阳制药厂历经6年,耗资百万元研制的主治手癣脚气病的国家级新药,正式被卫生部批准定名为“比之可”(沙苯立克复合散),并获得该部颁发的《新药证书》。与此同时,国家科委、国家技术监督局等5部委又为“比之可”颁发了《国家级新产品证书》。据现任厂长覃世清和“比之可”研制课题负责人、高级工程师胡世东介绍:该药1990年10月经卫生部批准立项,正式按国家
In this newsletter (correspondent Hu Zhendong Zhang Jianping), after nearly six years, the Changyang Pharmaceutical Factory in Hubei Province has spent six years developing state-level new drugs that were developed at a cost of one million yuan and were formally approved by the Ministry of Health as “more than enough” (Sha Benzocrack disperse) and obtain the “New Drug Certificate” issued by the Ministry. At the same time, five ministries and commissions such as the State Science and Technology Commission and the State Bureau of Technical Supervision issued the “National New Product Certificate” for “more than it is available.” According to Hu Shidong, the current director of the plant director Qu Shiqing and senior manager of the “Yi Zhike” research project, the drug was approved by the Ministry of Health in October 1990 and officially approved by the state.